Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goselasib Combination Therapy for First-Line Treatment of KRAS G12C Locally Advanced or Metastatic NSCLC
NCT07294261Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of garsorasib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
garsorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07294261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294261.